Glucagon manufacturing method

Through the coupling method of N-terminal tetrapeptide and C-terminal peptide, pseudoproline dipeptide is used to improve the synthesis efficiency of glucagon, solving the problems of low yield and low purity in the prior art, and achieving high efficiency and low cost pancreatic Preparation of hyperglycagon.

CN114401981BActive Publication Date: 2024-11-08BEIJING FRESENIUS KABI PHARM CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202080040921.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-06-18
Filing Date
2020-06-18
Publication Date
2024-11-08
Estimated Expiration
2040-06-18

AI Technical Summary

Technical Problem

The existing preparation methods for glucagon have problems of low yield, low purity and high cost. In particular, the yield and purity are often reduced due to peptide chain aggregation in solid phase peptide synthesis methods, and the recombinant DNA technology is complex and expensive.

Method used

The coupling method of N-terminal tetrapeptide and C-terminal peptide is adopted. The C-terminal peptide contains pseudoproline dipeptide. By selectively cleaving terminal protective groups and using coupling agents, the peptide sequence is extended to improve coupling efficiency, combined with SPPS or LPPS technology, Ensure efficient synthesis of glucagon.

Benefits of technology

High yield and high purity glucagon preparation is achieved, suitable for large-scale industrial production, reducing production costs and improving the industrial feasibility of the process.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0003388584490000011
    Figure BDA0003388584490000011
  • Figure BDA0003388584490000041
    Figure BDA0003388584490000041
  • Figure BDA0003388584490000051
    Figure BDA0003388584490000051
Patent Text Reader

Abstract

The present invention provides an improved method for preparing glucagon, the improved method comprising coupling an N-terminal tetramer fragment with a C-terminal peptide comprising at least one pseudo-proline. The method is very effective in avoiding aggregation and obtaining the desired product in high yield and purity.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention provides improved methods for preparing high purity glucagon and related intermediates. Background Art

[0002] Glucagon is a polypeptide hormone secreted by the α cells of the pancreatic islets of Langerhans. Glucagon is a single-chain peptide composed of 29 natural amino acids (SEQ ID NO: 1, glucagon 1-29), and is represented by the chemical structure shown below:

[0003]

[0004] Glucagon was first discovered in pancreatic extracts by chemists Kimball and Murlin in 1923. Glucagon is indicated for the treatment of severe hypoglycemia that can occur in patients treated with insulin or in the management of diabetics.

[0005] The earliest isolation of glucagon was from pancreatic extracts. Extraction from the pancreas is difficult and the product is largely contaminated with insulin. The above methods have low yields and therefore require large amounts of pancreas. In addition, animal-derived glucagon may induce allergic reactions in some patients, making it unsuitable for the described situation.

[0006] Currently, glucagon is produced by recombinant DNA technology or by using solid phase peptide synthesis (SPPS).Several patents such as US4826763 or US6110703 describe the synthesis of glucagon using recombinant DNA technology or genetically modified yeast cells.

[0007] Besides being extremely expensive, recombinant technology is also an industrially complex process. It requires the use of specialized equipment, modified organisms during synthesis, and elaborate analytical and purification procedures. In addition to the high cost, biotechnological methods for the production of biomolecules also suffer from low reproducibility.

[0008] Solid phase peptide synthesis of glucagon is relatively difficult because long peptide chains often aggregate on the resin due to intermolecular and intramolecular hydrogen bonding, resulting in several truncated sequences that appear as impurities, reducing the yield and purity of the final compound.

[0009] US Pat. No. 3,642,763 describes the synthesis of glucagon by condensing [aa 1-6] and [aa 7-29] peptide fragments in the presence of N-hydroxy-succinimide or N-hydroxyphthalimide and subsequently removing the protecting groups in the presence of trifluoroacetic acid. The patent does not disclose the purity of the compound obtained in the process.

[0010] Chinese patent CN103333239 describes a solid phase peptide synthesis method for glucagon, wherein the amino acid condensation is carried out at a higher temperature, and wherein the use of a pseudoproline dipeptide as a protecting group at positions 4 / 5 and 7 / 8 is disclosed. However, the purity of the glucagon obtained by the method is always low.

[0011] Therefore, there is a need for improved processes for the synthesis of glucagon which provide the product in high yield and purity and which are also cost-effective and industrially viable.

[0012] Purpose of the Invention

[0013] An object of the present invention is to overcome the above-mentioned disadvantages of the prior art.

[0014] Another object of the present invention is to provide an improved process for the preparation of glucagon which provides the product in high yield and high purity.

[0015] Another object of the present invention is to provide useful intermediates for the synthesis of glucagon. Summary of the invention

[0016] The present invention provides improved methods for preparing glucagon.

[0017] In one embodiment, the present invention relates to a method for preparing glucagon, comprising coupling an N-terminal tetrapeptide (1-4) (SEQ ID NO: 2) with a C-terminal peptide (5-29) (SEQ ID NO: 3), wherein the C-terminal peptide comprises at least one pseudo-proline dipeptide.

[0018] The sequence of the N-terminal tetrapeptide (1-4) is His(P)-Ser(P)-Gln(P)-Gly-OH, wherein P is a side chain protecting group or does not exist.

[0019] The C-terminal peptide (5-29) has the following amino acid sequence Thr(P)-Phe-Thr(P)-Ser(P)-Asp(P)-Tyr(P)-Ser(P)-Lys(P)-Tyr(P)-Leu-Asp(P)-Ser(P)-Arg(P)-Arg(P)-Ala-Gln(P)-Asp(P)-Phe-Val-Gln(P)-Trp(P)-Leu-Met-Asn(P)-Thr(P), wherein the sequence is further specified by the presence of at least one serine or threonine residue that has been reversibly protected as a proline-like acid-labile oxazolidine (also known as pseudoproline); and wherein P is a side chain protecting group or is absent.

[0020] The method of the present invention can be described as a method for preparing glucagon, the method comprising coupling the N-terminal tetrapeptide (1-4) of glucagon with the C-terminal peptide (5-29) of glucagon described above, wherein at least one serine or threonine in the C-terminal peptide is protected by using a pseudoproline dipeptide. In a preferred embodiment, the method for preparing glucagon comprises preparing the C-terminal peptide (5-29), the preparation comprising the following steps:

[0021] a) coupling α-amino protected threonine with a resin;

[0022] b) selective cleavage of terminal protecting groups;

[0023] c) coupling the subsequent α-amino protected amino acid or peptide with the deprotected amino group obtained in step b) in the presence of a coupling agent;

[0024] d) repeating steps b) and c) to extend the peptide sequence, thereby finally obtaining a C-terminal peptide (5-29);

[0025] Therein, at least one step c) comprises coupling with a pseudoproline dipeptide.

[0026] In one step, the peptide chain is extended by two residues by coupling with a pseudoproline dipeptide.

[0027] Another embodiment of the present invention is different pseudoproline dipeptides and their use for synthesizing glucagon. The pseudoproline dipeptide is preferably selected from the group consisting of:

[0028] Fmoc-Asp(OtBu)-Ser[psi(Me,Me)pro]-OH

[0029] Fmoc-Asn(Trt)-Thr[psi(Me,Me)pro]-OH

[0030] Fmoc-Tyr(tBu)-Ser[psi(Me,Me)pro]-OH

[0031] Fmoc-Phe-Thr[psi(Me,Me)pro]-OH and

[0032] Fmoc-Thr(tBu)-Ser[psi(Me,Me)pro]-OH.

[0033] More preferably, the method of the present invention provides the preparation of glucagon, which comprises the step of coupling the N-terminal tetrapeptide Boc-His(Trt)-Ser(tBu)-Gln(Trt)-Gly-OH(2) with the C-terminal peptide (5-29), wherein the C-terminal peptide comprises the pseudoproline dipeptide Asp(OtBu)-Ser[psi(Me,Me)pro].

[0034] Another embodiment of the present invention relates to a C-terminal peptide (5-29) and a protected glucagon sequence, which is an intermediate in the preparation of glucagon. DETAILED DESCRIPTION

[0035] The present invention relates to a method for preparing glucagon represented by formula I:

[0036]

[0037] Glucagon is also referred to by the following amino acid single letter code sequence:

[0038] HSQGTFTSDYSKYLDSRRAQDFVQWLMNT.

[0039] In the synthesis of large peptide molecules such as glucagon, the conformation of the growing peptide chain and its physicochemical properties are very important. The formation of secondary structures often leads to polymerization problems, which makes the coupling reaction incomplete, resulting in a decrease in the synthetic yield and purity of the final compound.

[0040] For example, it was found that in the stepwise SPPS preparation of glucagon, coupling efficiency was significantly reduced and efficient completion of the glucagon sequence was hampered after the insertion of the Gly4 residue (i.e., glycine at position 4). This was demonstrated by the presence of truncated sequences at residues Gly4, Gln3, and Ser2 in the crude glucagon (after cleavage from the resin) and by its very low HPLC purity (see Example 2, Batch 1A in the Experimental Section).

[0041] Similarly, intra- and intermolecular aggregation phenomena may be responsible for the decrease in the efficiency of the coupling reaction in glucagon synthesis even at the early stages of stepwise elongation, for example after the insertion of Leu 14. To address this issue, it was found that the use of a pseudoproline dipeptide allowed the coupling efficiency to be maintained during the synthesis of the C-terminal peptide (5-29) of glucagon.

[0042] However, the use of pseudoproline dipeptide was not sufficient to obtain crude glucagon in suitable yields (see Example 2, Batch 1B in the Experimental Section).

[0043] It was found that insertion of the last four amino acids (1-4) of the glucagon sequence in one step by a fragment-based synthesis approach involving coupling of the tetrapeptide His-Ser-Gln-Gly rather than coupling of Fmoc-Gly-OH resulted in a protected glucagon sequence with unexpectedly high purity.

[0044] On the one hand, the use of at least one pseudoproline dipeptide allows for efficient preparation of the C-terminal peptide (5-29) of glucagon. On the other hand, the coupling of the glucagon N-terminal tetrapeptide (1-4) with the C-terminal peptide (5-29) is very efficient and ultimately produces a crude product with good yield and high purity.

[0045] Therefore, the present invention provides a method for preparing glucagon, which method comprises coupling an optionally protected tetrapeptide (1-4) of glucagon with a C-terminal peptide (5-29) of glucagon, wherein the C-terminal peptide comprises at least one pseudoproline dipeptide.

[0046] The method of the invention can be performed by SPPS or by LPPS (liquid phase peptide synthesis) or by hybrid SPPS / LPPS techniques by adapting the conditions and methods described herein according to conventions well known to those skilled in the art.

[0047] The amino acids employed in the method of the present invention have the natural L-configuration; generally, the amino acids and pseudoproline dipeptides (preferably carrying a terminal protecting group) employed in the method of the present invention are commercially available.

[0048] As used herein, the term "terminal protecting group" refers to a protecting group of the α-amino group of the amino acid or peptide or complete glucagon sequence used to prepare glucagon, which is cleaved before coupling to extend the peptide sequence or at the end of peptide extension. Preferably, the terminal protecting group is 9-fluorenylmethoxycarbonyl (Fmoc) or tert-butyloxycarbonyl (Boc).

[0049] The term "resin" is used to describe a functionalized polymeric solid support suitable for performing peptide synthesis. Preferably, the resin herein may be selected from the group comprising: 2-chlorotriphenylmethyl chloride (CTC), triphenylmethyl chloride, Wang resin (Wang), Rink amide resin, Rink amide AM resin and Rink amide MBHA resin.

[0050] "Aggregation on the resin" refers to the formation of secondary structures or clumping of the peptide chain due to intra- and intermolecular hydrogen bonding interactions, which reduces the availability of the peptide for coupling reactions and hinders further growth of the peptide chain.

[0051] The term "pseudoproline" refers to an oxazolidine that, when the α-amino group and the side chain hydroxyl group of serine or threonine are simultaneously protected by cyclization with an aldehyde or ketone, produces an oxazolidine that exhibits structural features similar to proline (see also T. Haack, M. Mutter, Tetrahedron Lett. 1992, 33, 1589-1592). The pseudoproline dipeptide structure is depicted below, wherein the position of the Fmoc terminal protecting group is also indicated:

[0052]

[0053] wherein R1 is hydrogen or methyl; R2 is hydrogen for Ser and methyl for Thr; and R3 is the side chain of the amino acid next to the pseudoproline protected amino acid (configuration at the stereocenter not indicated).

[0054] The above-mentioned pseudoproline dipeptide is also indicated as Fmoc-A1-A2[psi(R1,R1)pro]-OH or more simply as pA1A2, wherein A1 and A2 are the three-letter or one-letter codes of the amino acids concerned and wherein, in the context of the present invention, A1 refers to aspartic acid, asparagine, tyrosine, phenylalanine or threonine and A2 refers to serine or threonine. In particular, when the pseudoproline dipeptide is incorporated into a peptide sequence, i.e., when it has no terminal group and no free carboxylic acid at the C-terminus, the abbreviation pA1A2 is used throughout the present disclosure.

[0055] The introduction of a pseudoproline dipeptide (e.g., an Fmoc-protected pseudoproline dipeptide) into a peptide sequence can be performed in solid phase under standard coupling conditions. Once the intact peptide is cleaved from the resin by acid hydrolysis, the pseudoproline is also hydrolyzed in the same step, providing two corresponding natural amino acids in the sequence. Cleavage of the pseudoproline protection performed after completion of peptide elongation occurs, for example, by acid treatment with a mixture comprising TFA.

[0056] As used herein, "side chain protecting groups" are protecting groups for amino acid side chain chemical functional groups that are not removed when the terminal protecting groups are removed and are stable during the coupling reaction. Preferably, side chain protecting groups are included to protect the side chains of particularly reactive or unstable amino acids to avoid side reactions and / or branching of growing molecules. Illustrative examples include acid-labile protecting groups such as tert-butyloxycarbonyl (Boc), alkyl groups such as tert-butyl (tBu), trityl (Trt), 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl (Pbf), etc. Other protecting groups can be effectively used because they are obvious to those skilled in the art.

[0057] The selection criteria for side chain protecting groups are that, in general, the protecting groups must be stable to the reaction conditions selected for removal of the terminal protecting groups at each step of the synthesis and must be removable after synthesis of the desired amino acid sequence is complete under reaction conditions that will not alter the peptide chain.

[0058] The term "C-terminal peptide" in the context of the present invention refers to a peptide of 25 amino acids in length which shares the C-terminal amino acid sequence of glucagon ending with a C-terminal threonine (Thr29). This sequence is referred to as SEQ ID NO: 3. When preparing glucagon according to the present invention and by SPPS, the C-terminal peptide can be attached to a resin via its C-terminus. The C-terminal peptide is further defined as having an α-amino group at the N-terminus which is capable of reacting with the carboxyl group of another amino acid or peptide.

[0059] The C-terminal peptide used according to the invention additionally comprises at least one pseudo-proline moiety. Said moiety is introduced via the pseudo-proline dipeptide used in the peptide elongation process.

[0060] In a preferred embodiment, the method for preparing glucagon comprises preparing a C-terminal peptide comprising said at least one pseudoproline moiety.

[0061] Another embodiment of the present invention relates to pseudoproline dipeptide and its use for synthesizing glucagon of the present invention.

[0062] Therefore, the method for preparing the glucagon of the present invention is characterized by using one or more different pseudoproline dipeptides which can be selected from the group consisting of:

[0063] Fmoc-Asp(P)-Ser[psi(R1,R1)pro]-OH (Fmoc-pDS)

[0064] Fmoc-Asn(P)-Thr[psi(R1,R1)pro]-OH (Fmoc-pNT)

[0065] Fmoc-Tyr(P)-Ser[psi(R1,R1)pro]-OH (Fmoc-pYS)

[0066] Fmoc-Phe-Thr[psi(R1,R1)pro]-OH (Fmoc-pFT) and

[0067] Fmoc-Thr(P)-Ser[psi(R1,R1)pro]-OH (Fmoc-pTS),

[0068] wherein P is a side chain protecting group or is absent, and R1 is hydrogen or methyl (Me).

[0069] Preferably, the pseudoproline dipeptide is selected from the group consisting of:

[0070] Fmoc-Asp(OtBu)-Ser[psi(Me,Me)pro]-OH

[0071] Fmoc-Asn(Trt)-Thr[psi(Me,Me)pro]-OH

[0072] Fmoc-Tyr(tBu)-Ser[psi(Me,Me)pro]-OH

[0073] Fmoc-Phe-Thr[psi(Me,Me)pro]-OH and

[0074] Fmoc-Thr(tBu)-Ser[psi(Me,Me)pro]-OH.

[0075] A preferred embodiment of the present invention is the use of Fmoc-Asp(OtBu)-Ser[psi(Me,Me)pro]-OH for the preparation of glucagon according to the method of the present invention. In particular, the introduction of the pseudoproline dipeptide Asp(OtBu)-Ser[psi(Me,Me)pro] to replace the residue Asp-Ser in positions 15-16 in the C-terminal peptide allows the peptide to be effectively extended until the Thr5 residue is inserted.

[0076] Therefore, the present invention provides a method for preparing glucagon, which method comprises preparing the C-terminal peptide according to steps a), b), c) and d) defined above, wherein at least one step c) comprises coupling with the pseudoproline dipeptide pDS, preferably with Fmoc-Asp(OtBu)-Ser[psi(Me,Me)pro]-OH according to positions 15-16 of the glucagon sequence.

[0077] Other embodiments of the present invention are the C-terminal peptide (5-29) of glucagon and its use in a method for preparing glucagon.

[0078] The C-terminal peptide comprises at least one pseudo-proline dipeptide pA1A2 and may be selected from the group comprising:

[0079] Thr(P)-Phe-Thr(P)-Ser(P)-Asp(P)-Tyr(P)-Ser(P)-Iys(P)-Tyr(P)-Leu-pDS-Arg(P) -Arg(P)-Ala-Gln(P)-Asp(P)-Phe-Val-Gln(P)-Trp(P)-Leu-Met-Asn(P)-Thr(P), (SEQ ID NO:4)

[0080] Thr(P)-Phe-Thr(P)-Ser(P)-Asp(P)-pYS-Lys(P)-Tyr(P)-Leu-Asp(P)-Ser(P)-Arg(P) -Arg(P)-Ala-Gln(P)-Asp(P)-Phe-Val-Gln(P)-Trp(P)-Leu-Met-Asn(P)-Thr(P), (SEQ ID NO:5)

[0081] Thr(P)-Phe-Thr(P)-Ser(P)-Asp(P)-pYS-Lys(P)-Tyr(P)-Leu-pDS-Arg(P)-Arg(P)-Ala-Gin(P)-Asp(P)-Phe-Val-Gln(P)-Trp(P)-Leu-Met-Asn(P)-Thr(P), (SEQ ID NO:6)

[0082] Thr(P)-Phe-pTS-Asp(P)-Tyr(P)-Ser(P)-Lys(P)-Tyr(P)-Leu-Asp(P)-Ser(P)-Arg(P) -Arg(P)-Ala-Gln(P)-Asp(P)-Phe-Val-Gln(P)-Trp(P)-Leu-Met-Asn(P)-Thr(P), (SEQ ID NO:7)

[0083] Thr(P)-Phe-pTS-Asp(P)-Tyr(P)-Ser(P)-Lys(P)-Tyr(P)-Leu-pDS-Arg(P)-Arg(P)-Ala-Gln(P)-Asp(P)-Phe-Val-Gln(P)-Trp(P)-Leu-Met-Asn(P)-Thr(P), (SEQ ID NO:8)

[0084] Thr(P)-pFT-Ser(P)-Asp(P)-Tyr(P)-Ser(P)-Lys(P)-Tyr(P)-Leu-Asp(P)-Ser(P)-Arg( P)-Arg(P)-Ala-Gln(P)-Asp(P)-Phe-Val-Gln(P)-Trp(P)-Leu-Met-Asn(P)-Thr(P), (SEQ ID NO:9)

[0085] and

[0086] Thr(P)-pFT-Ser(P)-Asp(P)-Tyr(P)-Ser(P)-Lys(P)-Tyr(P)-Leu-pDS-Arg(P)-Arg(P)-Ala-Gln(P)-Asp(P)-Phe-Val-Gln(P)-Trp(P)-Leu-Met-Asn(P)-Thr(P), (SEQ IDNO:10)

[0087] wherein P is a side chain protecting group or is absent, and pA1A2 is a pseudoproline dipeptide as defined above.

[0088] The C-terminal peptide (5-29) is generally indicated as SEQ D NO: 3 when it does not carry a pseudoproline dipeptide as a protection unit, while SEQ ID NO: 4 to SEQ ID NO: 10 are specific examples comprising specific pseudoprolines at the positions specified above.

[0089] In one embodiment, the above-mentioned optionally protected C-terminal peptide (5-29) of glucagon is attached at its C-terminus to a solid support, preferably to Wang resin.

[0090] In another embodiment, the optionally protected C-terminal peptide (5-29) of glucagon described above is also protected by a terminal protecting group, preferably by Fmoc.

[0091] Preferably, the C-terminal peptide (5-29) of glucagon used to prepare the present invention is:

[0092] Thr(P)-Phe-Thr(P)-Ser(P)-Asp(P)-Tyr(P)-Ser(P)-Iys(P)-Tyr(P)-Leu-pDS-Arg(P) -Arg(P)-Ala-Gln(P)-Asp(P)-Phe-Val-Gln(P)-Trp(P)-Leu-Met-Asn(P)-Thr(P), (SEQ ID NO:4)

[0093] wherein P and pDS are as defined above.

[0094] Most preferably, the C-terminal peptide used to prepare glucagon is

[0095] Thr(tBu)-Phe-Thr(tBu)-Ser(tBu)-Asp(tBu)-Tyr(tBu)-Ser(tBu)-Lys(Boc)-Tyr(tBu)-Leu-pDS-Arg(Pb f)-Arg(Pbf)-Ala-Gln(Trt)-Asp(tBu)-Phe-Val-Gln(Trt)-Trp(Boc)-Leu-Met-Asn(Trt)-Thr(tBu), (4a)

[0096] Among them, pDS is Asp(OtBu)-Ser[psi(Me,Me)pro].

[0097] Another aspect of the present invention relates to an N-terminal tetrameric peptide (1-4) (or tetrapeptide) for synthesizing glucagon of the present invention coupled to a C-terminal peptide (5-29) of glucagon, namely:

[0098] His(P)-Ser(P)-Gln(P)-Gly-OH (SEQ ID NO: 2)

[0099] Wherein, P is a side chain protecting group or does not exist.

[0100] The above tetrameric peptide is preferably protected by a terminal protecting group at the α-amino group (of histidine). Preferably, the terminal protecting group is of the carbamate type, such as 9-fluorenylmethoxycarbonyl (Fmoc) or tert-butyloxycarbonyl (Boc). More preferably, the terminal protecting group of the tetrameric peptide is Boc. In a preferred embodiment, the tetrameric peptide used in the method of the present invention is Boc-His (Trt) -Ser (tBu) -Gln (Trt) -Gly-OH (2a).

[0101] The N-terminal peptide (1-4) is generally indicated as SEQ ID NO: 2, while 2a is a specific example comprising the specified protecting groups.

[0102] Preferably, the C-terminal peptide and the N-terminal tetrameric peptide are prepared using SPPS by stepwise coupling of amino acids or peptides according to a desired sequence with a C-terminal amino acid attached to a resin using at least one coupling agent and additives.

[0103] For the preparation of tetrameric peptides, CTC resin is preferably used; for the preparation of C-terminal peptides, Wang resin is preferably used.

[0104] The resin is activated by removing the protecting groups. The activated resin is coupled with the first amino acid, ie, Thr29 or Gly4, wherein the amino acid is protected by a terminal protecting group and optionally a side chain protecting group.

[0105] The terminal protecting group is cleaved under appropriate conditions depending on its type.

[0106] When using the Fmoc group, it can be removed by treating under alkaline conditions. The base used can be an inorganic or organic base. Preferably, the base is an organic base selected from the group comprising piperidine, pyrrolidine, piperazine, tert-butylamine, DBU and diethylamine, preferably piperidine.

[0107] When a Boc group is used, it can be removed by treatment under acidic conditions. The acid can be an inorganic or organic acid known to any person skilled in the art. Preferably, the acid is TFA at a suitable concentration.

[0108] The coupling of the amino acid occurs in the presence of a coupling agent. The coupling agent may be selected from the group comprising N,N'-diisopropylcarbodiimide (DIC), N,N'-dicyclohexylcarbodiimide (DCC), (benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyBOP), N,N,N',N'-tetramethyl-O-(benzotriazol-1-yl)uronium tetrafluoroborate (TBTU), 2-(7-aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU), 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) and ethyl-dimethylaminopropylcarbodiimide (EDC), etc. Preferably, the reaction is carried out in the presence of N,N'-diisopropylcarbodiimide.

[0109] In a preferred aspect of the present invention, the coupling step is also performed in the presence of an additive. When used in the coupling reaction, the presence of the additive reduces the loss of configuration at the carboxylic acid residue, increases the coupling rate and reduces the risk of racemization. The additive can be selected from the group comprising: 1-hydroxybenzotriazole (HOBt), 2-hydroxypyridine N-oxide, N-hydroxysuccinimide, 1-hydroxy-7-azabenzotriazole (HOAt), endo-N-hydroxy-5-norbornene-2,3-dicarboxamide and 2-cyano-2-hydroxyimino-ethyl acetate (OxymaPure), 5-(hydroxyimino)1,3-dimethylpyrimidine-2,4,6-(1H,3H,5H)-trione (Oxyma B). Preferably, the coupling reaction is carried out in the presence of 2-cyano-2-hydroxyimino-ethyl acetate or 5-(hydroxyimino)1,3-dimethylpyrimidine-2,4,6-(1H,3H,5H)-trione.

[0110] The coupling reaction can be carried out in the presence of a base selected from the group consisting of tertiary amines including diisopropylethylamine (DIEA), triethylamine, N-methylmorpholine, N-methylpiperidine, etc.; preferably, the reaction is carried out in the presence of DIEA.

[0111] The coupling reaction involving the peptide or amino acid occurs in the presence of a solvent selected from the group consisting of dimethylformamide, dimethylacetamide, dimethyl sulfoxide, dichloromethane, chloroform, tetrahydrofuran, 2-methyltetrahydrofuran and N-methylpyrrolidine.

[0112] Additionally, unreacted sites on the resin are optionally blocked by brief treatment with a large excess of a highly reactive non-hindering reagent selected based on the unreacted site to be blocked and according to well-known peptide synthesis techniques to avoid truncating the sequence and prevent any side reactions.

[0113] Once the desired peptide sequence has been obtained, it is necessary to cleave the N-terminal tetramer from the solid support to release the carboxylic acid of Gly4 and provide His(P)-Ser(P)-Gln(P)-Gly-OH, which is optionally protected by a terminal protecting group. The cleavage is carried out under conditions suitable for the solid support employed and suitable for maintaining any protection of the peptide sequence, such as the terminal protecting group and any side chain protecting group P. For example, when using CTC resin, the cleavage is carried out in an acid solution, such as a 1% TFA DCM solution.

[0114] Once the desired peptide sequence has been obtained, the terminal protecting group on the C-terminal peptide is cleaved to release the α-amino group, thereby making the C-terminal peptide ready for final coupling with the N-terminal tetramer.

[0115] The present invention provides a method for preparing glucagon, the method comprising the step of coupling an N-terminal tetrapeptide (1-4) with a C-terminal peptide (5-29) to obtain a glucagon peptide sequence. With respect to the coupling of the method of the present invention, all of the above features apply mutatis mutandis. In particular, reference is made to the coupling reaction conditions including coupling agents, additives, solvents, protecting groups, conditions for cleavage of terminal protecting groups, all of which can be easily adjusted in a clear manner by a person skilled in the art.

[0116] In yet another aspect, the present invention thus relates to various optionally protected glucagon sequences or fragments which are intermediates in the synthesis of glucagon. The peptide sequence may be selected from the group comprising:

[0117] His(P)-Ser(P)-Gln(P)-Gly-Thr(P)-Phe-Thr(P)-Ser(P)-Asp(P)-Tyr(P)-Ser(P)-Lys(P)-Tyr(P)-Leu-pDS-Arg(P)-Arg(P)-Ala-Gln(P)-Asp(P)-Phe-Val-Gln(P)-Trp(P)-Leu-Met-Asn(P)-Thr(P),

[0118] (SEQ ID NO:11)

[0119] His(P)-Ser(P)-Gln(P)-Gly-Thr(P)-Phe-Thr(P)-Ser(P)-Asp(P)-pYS-Lys(P)-Tyr(P)-Leu-Asp(P)-Ser(P)-Arg(P)-Arg(P)-Ala-Gln(P)-Asp(P)-Phe-Val-Gln(P)-Trp(P)-Leu-Met-Asn(P)-Thr(P),(SEQ ID NO:12)

[0120] His(P)-Ser(P)-Gln(P)-Gly-Thr(P)-Phe-Thr(P)-Ser(P)-Asp(P)-pYS-Lys(P)-Tyr(P)-Leu-pDS-Arg(P)-Arg(P)-Ala-Gln(P)-Asp(P)-Phe-Val-Gln(P)-Trp(P)-Leu-Met-Asn(P)-Thr(P),

[0121] (SEQ ID NO:13)

[0122] His(P)-Ser(P)-Gln(P)-Gly-Thr(P)-Phe-pTS-Asp(P)-Tyr(P)-Ser(P)-Lys(P)-Tyr(P)-Leu-Asp(P)-Ser(P)-Arg(P)-Arg(P)-Ala-Gln(P)-Asp(P)-Phe-Val-Gln(P)-Trp(P)-Leu-Met-Asn(P)-Thr(P),

[0123] (SEQ ID NO:14)

[0124] His(P)-Ser(P)-Gln(P)-Gly-Thr(P)-Phe-pTS-Asp(P)-Tyr(P)-Ser(P)-Iys(P)-Tyr(P)-Leu- pDS-Arg(P)-Arg(P)-Ala-Gln(P)-Asp(P)-Phe-Val-Gln(P)-Trp(P)-Leu-Met-Asn(P)-Thr(P),

[0125] (SEQ ID NO: 15)

[0126] His(P)-Ser(P)-Gln(P)-Gly-Thr(P)-pFT-Ser(P)-Asp(P)-Tyr(P)-Ser(P)-Lys(P)-Tyr(P)-Leu-Asp( P)-Ser(P)-Arg(P)-Arg(P)-Ala-Gln(P)-Asp(P)-Phe-Val-Gln(P)-Trp(P)-Leu-Met-Asn(P)-Thr(P),

[0127] (SEQ ID NO: 16)

[0128] and

[0129] His(P)-Ser(P)-Gln(P)-Gly-Thr(P)-pFT-Ser(P)-Asp(P)-Tyr(P)-Ser(P)-Lys(P)-Tyr(P)-Leu -pDS-Arg(P)-Arg(P)-Ala-Gln(P)-Asp(P)-Phe-Val-Gln(P)-Trp(P)-Leu-Met-Asn(P)-Thr(P),

[0130] (SEQ ID NO: 17),

[0131] wherein P is a side chain protecting group or is absent, and pA1A2 is a pseudoproline dipeptide as defined above.

[0132] The glucagon peptide sequence (1-29) is indicated as SEQ ID NO: 1, while the above sequences represented as SEQ ID NOs 11-17 are specific examples of glucagon sequences comprising one or more pseudoproline dipeptides as protected moieties at the specified positions.

[0133] In one embodiment, the above optionally protected intermediate glucagon sequence is attached at its C-terminus to a solid support, preferably to a Wang resin.

[0134] In another embodiment, the above optionally protected intermediate glucagon sequence is also protected by a terminal protecting group, preferably Boc.

[0135] In a preferred embodiment, the protected glucagon sequence as an intermediate in the synthesis of glucagon is

[0136] His(P)-Ser(P)-Gln(P)-Gly-Thr(P)-Phe-Thr(P)-Ser(P)-Asp(P)-Tyr(P)-Ser(P)-Lys(P)-Tyr(P) -Leu-pDS-Arg(P)-Arg(P)-Ala-Gln(P)-Asp(P)-Phe-Val-Gln(P)-Trp(P)-Leu-Met-Asn(P)-Thr(P)

[0137] (SEQ ID NO: 11).

[0138] In an even more preferred embodiment, the protected sequence of the intermediate in the method for preparing glucagon of the present invention is

[0139] Boc-His(Trt)-Ser(tBu)-Gln(Trt)-Gly-Thr(tBu)-Phe-Thr(tBu)-Ser(tBu)-Asp(tBu)-Tyr(tBu)-Ser(tBu)-Lys(Boc)-Tyr(tBu) -Leu-pDS-Arg(Pbf)-Arg(Pbf)-Ala-Gln(Trt)-Asp(tBu)-Phe-Val-Gln(Trt)-Trp(Boc)-Leu-Met-Asn(Trt)-Thr(tBu)-Wang's resin (11a).

[0140] Further deprotection of the protected glucagon sequence provides crude glucagon, which can optionally be purified.

[0141] In a preferred embodiment, when SPPS is used, the protected glucagon sequence is ultimately deprotected and cleaved from the resin, either simultaneously or in two steps, to provide crude glucagon, which may optionally be purified.

[0142] Deprotection and cleavage conditions generally depend on the nature of the protecting group and the resin used: in a preferred embodiment, deprotection and cleavage are performed by acid treatment; preferably, by treatment with a mixture containing an acid such as trifluoroacetic acid (TFA) or the like. Optionally, the cleavage mixture may contain one or more scavengers. Scavengers are substances such as anisole, thioanisole, triisopropylsilane (TIS), 1,2-ethanedithiol (EDT) and phenol that can minimize the modification or destruction of sensitive deprotection side chains such as arginine residues in the cleavage environment.

[0143] For example, when Wang resin is used, the cleavage / deprotection step is preferably performed by using a mixture comprising TFA, TIS and EDT, such as TFA / TIS / H2O / EDT / L-methionine / NH4I (92.5:2:2:2:1:0.5 v / v / v / v / w / w) mixture. The crude glucagon obtained can be optionally purified by crystallization or chromatography techniques well known in the art.

[0144] The inventors of the process of the present invention have found that the use of the coupling between the above N-terminal tetrapeptide (1-4) and the C-terminal peptide (5-29) as defined above and according to the above method provides glucagon in high yield and high purity, making it suitable for large-scale industrial production.

[0145] abbreviation

[0146] SPPS Solid Phase Peptide Synthesis

[0147] LPPS Liquid Phase Peptide Synthesis

[0148] MBHA resin methylbenzhydrylamide resin

[0149] Fmoc 9-fluorenylmethoxycarbonyl

[0150] Boc tert-Butyloxycarbonyl

[0151] Trt Trityl

[0152] tBu tert-butyl

[0153] Pbf 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl

[0154] HPLC High Performance Liquid Chromatography

[0155] h / min hours / minutes

[0156] DIEA Diisopropylethylamine

[0157] DBU 1,8-diazabicyclo[5.4.0]undec-7-ene

[0158] DMAP 4-dimethylaminopyridine TFA trifluoroacetic acid

[0159] Ac2O Acetic anhydride

[0160] DMF N,N-Dimethylformamide

[0161] DCM Dichloromethane

[0162] ACN Acetonitrile

[0163] MeOH Methanol

[0164] DIPE Diisopropyl ether

[0165] TIS Triisopropylsilane

[0166] EDT 1,2-Ethanedithiol

[0167] DIC Diisopropylcarbodiimide

[0168] DCC Dicyclohexylcarbodiimide

[0169] EDC Ethyl-dimethylaminopropylcarbodiimide

[0170] HOBt 1-Hydroxybenzotriazole

[0171] HOAt 1-Hydroxy-7-azabenzotriazole

[0172] TBTU N,N,N',N'-Tetramethyl-O-(benzotriazol-1-yl)uronium tetrafluoroborate

[0173] HBTU 3-[Bis(dimethylamino)methylimidazolium]-3H-benzotriazole-1-oxide hexafluorophosphate

[0174] HATU 2-(7-Aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate

[0175] PyBOP (Benzotriazol-1-yloxy)-tripyrrolidinophosphonium hexafluorophosphate

[0176] Oxyma / OxymaPure 2-Cyano-2-hydroxyimino-acetic acid ethyl ester

[0177] Oxyma B 5-(Hydroxyimino)1,3-dimethylpyrimidine-2,4,6-(1H,3H,5H)-trione

[0178] Experimental Section

[0179] Detailed experimental conditions suitable for preparing the glucagon of the present invention are provided by the following examples, which are intended to illustrate but not to limit all possible embodiments of the present invention.

[0180] Unless otherwise noted, all materials, solvents, and reagents were obtained from commercial suppliers of the highest grade and used without further purification.

[0181] The assay (%) was calculated by HPLC comparing the peak area of ​​the sample with that of the standard. The molar yield (%) was calculated taking into account the final number of moles obtained (based on the assay) divided by the initial number of moles.

[0182] Example 1. Synthesis of Boc-His(Trt)-Ser(tBu)-Gln(Trt)-Gly-OH

[0183] The synthesis of the title tetrapeptide was carried out on CTC resin (2 grams) by SPPS. After the resin was swollen with DCM (20 mL), Fmoc-Gly-OH (1 eq in terms of resin loading) and DIEA (2 eq) dissolved in DCM (12 mL) were added to the resin and reacted for 1 hour. Then, the resin was washed with DCM (3 × 12 mL), and the residual free chlorine group was replaced with the DCM containing MeOH and DIEA. The residual hydroxyl groups were capped with DCM containing 0.5 MAc2O (12 mL, 15 minutes) and washed with DCM (3 × 12 mL). Then, the resin was swollen for 30 minutes with DMF (12 mL). The Fmoc group was removed by processing with DMF containing 20% ​​piperidine (2 × 12 mL, 10 minutes per cycle), and washed with DMF (4 × 12 mL, 2 × 5 minutes and 2 × 10 minutes). The resin loading after insertion of the first amino acid was estimated by UV measurement of the deprotected solution at 301 nm, giving a loading of 1.2 mmol / g.

[0184] The next amino acids used in the peptide extension are as follows (listed from first to last): Fmoc-Gln(Trt)-OH, Fmoc-Ser(tBu)-OH, and Boc-His(Trt)-OH.

[0185] Except for the Boc-His(Trt)-OH residue, Fmoc-amino acids (2 eq in terms of resin loading, 4.8 mmol in this case) were preactivated with DIC (2 eq) and OxymaPure (2 eq) for 3 minutes, then added to the resin and allowed to couple for 60 minutes. Oxyma B was used instead of OxymaPure to activate Boc-His(Trt)-OH. After peptide chain termination, the peptidyl resin was washed with DMF (3×12 mL), DCM (3×12 mL) and dried to constant weight. The fully protected peptide was obtained by treatment with a 1% TFA solution in DCM (10 mL×5; stirring for 15 minutes each time). The cleavage mixture was pooled, washed with water and precipitated with DIPE (150 ml in terms of cleavage mixture volume).

[0186] The solid was filtered, washed three more times with 20 mL DIPE, and dried under vacuum to give 2.4 g crude Boc-His(Trt)-Ser(tBu)-Gln(Trt)-Gly-OH (2.2 mmol) with HPLC purity of 97%. Molar yield: 91.6%.

[0187] Example 2. Preparation of glucagon

[0188] Resin loading

[0189] Glucagon synthesis was performed on Wang resin (3 grams) by SPPS. After swelling the resin with DMF (10 mL), Fmoc-Thr(tBu)-OH (4 eq in terms of resin loading) was preactivated with DIC and DMAP (2 eq and 0.1 eq, respectively) in DMF (18 mL) for 5 minutes, then added to the resin and allowed to couple for 60 minutes. The resin was then washed with DMF (3×6 mL), and the remaining free hydroxyl groups were capped with DMF containing 0.5 M Ac2O (6 mL, 15 minutes) and washed with DMF (3×6 mL). The Fmoc group was removed by treatment with DMF containing 20% ​​piperidine (2×6 mL, 10 minutes per cycle), and washed with DMF (4×6 mL, 2×5 minutes and 2×10 minutes). The resin loading after insertion of the first amino acid was evaluated by UV measurement of the deprotection solution at 301 nm, resulting in a loading of 0.7 mmol / g.

[0190] The resin thus obtained was divided into three portions (1 gram of starting resin each): one portion was used for the SPPS synthesis of glucagon, which used only standard Fmoc-protected amino acids (Batch 1A); the second portion used the pseudoproline dipeptide residue Fmoc-Asp(OtBu)-Ser[psi(Me,Me)pro]-OH (position 15-16, Batch 1B); and the third portion used the pseudoproline dipeptide residue Fmoc-Asp(OtBu)-Ser[psi(Me,Me)pro]-OH and the tetrapeptide Boc-His(Trt)-Ser(tBu)-Gln(Trt)-Gly-OH (Batch 1C).

[0191] Batch 1A (reference)

[0192] The preparation was carried out by using the following amino acids, listed from the first to the last, attached to the H-Thr-Wang resin obtained as described above:

[0193] Fmoc-Asn(Trt)-OH, Fmoc-Met-OH, Fmoc-Leu-OH, Fmoc-Trp(Boc)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Val-OH, Fmoc-Phe-OH, Fmoc-Asp( tBu)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Ala-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Asp(tBu)-OH, Fmoc -Leu-OH, Fmoc-Tyr(tBu)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Tyr(tBu)-OH, Fmoc-Asp(tBu)-OH, Fmoc-Ser(tBu)-OH , Fmoc-Thr(tBu)-OH, Fmoc-Phe-OH, Fmoc-Thr(tBu)-OH, Fmoc-Gly-OH, Fmoc-Gln(Trt)-OH, Fmoc-Ser(tBu)-OH, Boc-His(Trt)-OH.

[0194] In each step, the Fmoc-protected amino acid (4 eq, i.e. 2.8 mmol in terms of resin loading) was pre-activated with DIC (4 eq) and OxymaPure (4 eq) in DMF (6 mL) for 3 minutes, then added to the resin and allowed to couple for 60 minutes. After each coupling, unreacted amino groups were capped using DMF containing 0.5 M Ac2O. The Fmoc group was removed by treatment with 20% piperidine in DMF (2×6 mL, 10 minutes per cycle), followed by washing the resin with DMF (4×6 mL, 2×5 minutes and 2×10 minutes) to allow insertion of the next amino acid residue. After the peptide sequence was complete, the peptidyl resin was washed with DMF (3×6 mL), DCM (3×6 mL) and dried to constant weight. The dried peptidyl resin was suspended in 20 mL of a mixture of TFA / TIS / H2O / EDT / methionine / NH4I (92.5:2:2:2:1:0.5 v / v / v / v / w / w), precooled to 0-5°C and stirred at room temperature for 4 hours. The resin was filtered off and cold diisopropyl ether (80 mL) was added to the solution. The resulting light yellow suspension was stirred at 0-5°C. The solid was filtered, washed three more times with 20 mL of diisopropyl ether and dried under vacuum to give 2.4 g of crude glucagon (0.10 mmol, assay 15%) with an HPLC purity of 37%. Molar yield: 15%.

[0195] Batch 1B (reference)

[0196] The preparation was carried out by taking the following amino acids and peptides, which were ordered from the first to the last, and attaching them to the H-Thr-Wang resin obtained as described above:

[0197] Fmoc-Asn(Trt)-OH、Fmoc-Met-OH、Fmoc-Leu-OH、Fmoc-Trp(Boc)-OH、Fmoc-Gln(Trt)-OH、Fmoc-Val-OH、Fmoc-Phe-OH、Fmoc-Asp(tBu)-OH、Fmoc-Gln(Trt)-OH、Fmoc-Ala-OH、Fmoc-Arg(Pbf)-OH、Fmoc-Arg(Pbf)-OH、Fmoc-Asp(OtBu)-Ser[psi(Me,Me)pro]-OH、Fmoc-Leu-OH、Fmoc-Tyr(tBu)-OH、Fmoc-Lys(Boc)-OH、Fmoc-Ser(tBu)-OH、Fmoc-Tyr(tBu)-OH、Fmoc-Asp(tBu)-OH、Fmoc-Ser(tBu)-OH、Fmoc-Thr(tBu)-OH、Fmoc-Phe-OH、Fmoc-Thr(tBu)-OH、Fmoc-Gly-OH、Fmoc-Gln(Trt)-OH、Fmoc-Ser(tBu)-OH、Boc-His(Trt)-OH。

[0198] In each step, the Fmoc protected amino acid (4 eq, i.e. 2.8 mmol in terms of resin loading) was preactivated with DIC (4 eq) and OxymaPure (4 eq) in DMF (6 mL) for 3 min, then added to the resin and allowed to couple for 60 min. After preactivation with DIC and OxymaPure (3 eq) in DMF (6 mL) for 3 min, the pseudoproline residue Fmoc-Asp(OtBu)-Ser[psi(Me,Me)pro]-OH (3 eq) was coupled, then added to the resin and allowed to couple for 90 min. After each coupling, the unreacted amino groups were capped using 0.5 M Ac2O in DMF. The Fmoc group was removed by treatment with 20% piperidine in DMF (2×6 mL, 10 min each cycle), followed by washing the resin with DMF (4×6 mL, 2×5 min and 2×10 min) to allow insertion of the next residue. After the peptide sequence was complete, the peptidyl resin was washed with DMF (3×6 mL), DCM (3×6 mL) and dried to constant weight. The dried peptidyl resin was suspended in 20 mL of TFA / TIS / H2O / EDT / L-methionine / NH4I (92.5:2:2:2:1:0.5 v / v / v / v / w / w) mixture, precooled to 0-5°C and stirred at room temperature for 4 hours. The resin was filtered off and cold diisopropyl ether (80 ml) was added to the solution. The obtained light yellow suspension was stirred at 0-5°C. The solid was filtered, washed 3 more times with 20 mL of diisopropyl ether and vacuum dried to give 1.7 g of crude glucagon (0.02 mmol, assay 4%) with an HPLC purity of 8%. Molar yield: 3%.

[0199] Batch 1C

[0200] The preparation was carried out by taking the following amino acids and peptides, which were ordered from the first to the last, and attaching them to the H-Thr-Wang resin obtained as described above:

[0201] Fmoc-Asn(Trt)-OH、Fmoc-Met-OH、Fmoc-Leu-OH、Fmoc-Trp(Boc)-OH、Fmoc-Gln(Trt)-OH、Fmoc-Val-OH、Fmoc-Phe-OH、Fmoc-Asp(tBu)-OH、Fmoc-Gln(Trt)-OH、Fmoc-Ala-OH、Fmoc-Arg(Pbf)-OH、Fmoc-Arg(Pbf)-OH、Fmoc-Asp(OtBu)-Ser[psi(Me,Me)pro]-OH、Fmoc-Leu-OH、Fmoc-Tyr(tBu)-OH、Fmoc-Lys(Boc)-OH、Fmoc-Ser(tBu)-OH、Fmoc-Tyr(tBu)-OH、Fmoc-Asp(tBu)-OH、Fmoc-Ser(tBu)-OH、Fmoc-Thr(tBu)-OH、Fmoc-Phe-OH、Fmoc-Thr(tBu)-OH、Boc-His(Trt)-Ser(tBu)-Gln(Trt)-Gly-OH。

[0202] In each step, the Fmoc protected amino acid (4 eq, i.e. 2.8 mmol in terms of resin loading) was preactivated with DIC (4 eq) and OxymaPure (4 eq) in DMF (6 mL) for 3 minutes, then added to the resin and allowed to couple for 60 minutes. After preactivation with DIC and OxymaPure (2 eq) in DMF (16 mL) at 40° C. for 15 minutes, the pseudoproline residue Fmoc-Asp(OtBu)-Ser[psi(Me,Me)pro]-OH (3 eq, i.e. 2.1 mmol) was coupled with the tetrapeptide Boc-His(Trt)-Ser(tBu)-Gln(Trt)-Gly-OH (2 eq), then added to the resin and allowed to couple for 180 minutes. After each coupling, the unreacted amino groups were capped using 0.5 M Ac2O in DMF. The Fmoc group is removed by treating with DMF (2 × 6 mL, 10 minutes per cycle) containing 20% ​​piperidine, and washed with DMF (4 × 6 mL, 2 × 5 minutes and 2 × 10 minutes) to allow the insertion of the next residue. After the peptide sequence is complete, the peptidyl resin is washed with DMF (3 × 6 mL), DCM (3 × 6 mL) and dried to constant weight. The dry peptidyl resin is suspended in a 20 mL TFA / TIS / H2O / EDT / L-methionine / NH4I (92.5: 2: 2: 2: 1: 0.5 v / v / v / v / w / w) mixture, precooled to 0-5 ° C and stirred at room temperature for 4 hours. Filter out the resin, and add cold diisopropyl ether (80 ml) to the solution. Stir the obtained light yellow suspension at 0-5 ° C. The solid was filtered, washed three more times with 20 mL of diisopropyl ether and dried under vacuum to give 2.75 g of crude glucagon (0.40 mmol, assay 5α%) with HPLC purity of 80%. Molar yield: 58%. SEQUENCE LISTING <110> Fresenius Kabi iPSUM Srl <120> Glucagon manufacturing method <130> FK19104-05-PAT-WO <150> EP19180875.7 <151> 2019-06-18 <160> 17 <170> PatentIn version 3.5 <210> 1 <211> 29 <212> PRT <213> Human <220> <221> <222> (1)..(29) <223> Glucagon <400> 1 His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser 1 5 10 15 Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Met Asn Thr 20 25 <210> 2 <211> 4 <212> PRT <213> Artificial Sequence <220> <221> <222> (1)..(4) <223> N-terminal peptide (1-4) <400> 2 His Ser Gln Gly 1 <210> 3 <211> 25 <212> PRT <213> Artificial Sequence <220> <221> <222> (1)..(25) <223> C-terminal peptide (5-29) <400> 3 Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser Arg Arg Ala Gln 1 5 10 15 Asp Phe Val Gln Trp Leu Met Asn Thr 20 25 <210> 4 <211> 25 <212> PRT <213> Artificial Sequence <220> <223> C-terminal peptide containing pseudoproline pDS <220> <221> XA <222> (11)..(12) <223> Asp-Ser pseudoproline dipeptide <400> 4 Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Xaa Xaa Arg Arg Ala Gln 1 5 10 15 Asp Phe Val Gln Trp Leu Met Asn Thr 20 25 <210> 5 <211> 25 <212> PRT <213> Artificial Sequence <220> <223> C-terminal peptide containing pseudoproline pYS <220> <221> XA <222> (6)..(7) <223> Tyr-Ser pseudoproline dipeptide <400> 5 Thr Phe Thr Ser Asp Xaa Xaa Lys Tyr Leu Asp Ser Arg Arg Ala Gln 1 5 10 15 Asp Phe Val Gln Trp Leu Met Asn Thr 20 25 <210> 6 <211> 25 <212> PRT <213> Artificial Sequence <220> <223> C-terminal peptide containing pseudoprolines pYS and pDS <220> <221> XA <222> (6)..(7) <223> Tyr-Ser pseudoproline dipeptide <220> <221> XA <222> (11)..(12) <223> Asp-Ser pseudoproline dipeptide <400> 6 Thr Phe Thr Ser Asp Xaa Xaa Lys Tyr Leu Xaa Xaa Arg Arg Ala Gln 1 5 10 15 Asp Phe Val Gln Trp Leu Met Asn Thr 20 25 <210> 7 <211> 25 <212> PRT <213> Artificial Sequence <220> <223> C-terminal peptide containing pseudoproline pTS <220> <221> XA <222> (3)..(4) <223> Thr-Ser pseudoproline dipeptide <400> 7 Thr Phe Xaa Xaa Asp Tyr Ser Lys Tyr Leu Asp Ser Arg Arg Ala Gln 1 5 10 15 Asp Phe Val Gln Trp Leu Met Asn Thr 20 25 <210> 8 <211> 25 <212> PRT <213> Artificial Sequence <220> <223> C-terminal peptide containing pseudoproline pTS and pDS <220> <221> XA <222> (3)..(4) <223> Thr-Ser pseudoproline dipeptide <220> <221> XA <222> (11)..(12) <223> Asp-Ser pseudoproline dipeptide <400> 8 Thr Phe Xaa Xaa Asp Tyr Ser Lys Tyr Leu Xaa Xaa Arg Arg Ala Gln 1 5 10 15 Asp Phe Val Gln Trp Leu Met Asn Thr 20 25 <210> 9 <211> 25 <212> PRT <213> Artificial Sequence <220> <223> C-terminal peptide containing pseudoproline pFT <220> <221> XA <222> (2)..(3) <223> Phe-Thr pseudoproline dipeptide <400> 9 Thr Xaa Xaa Ser Asp Tyr Ser Lys Tyr Leu Asp Ser Arg Arg Ala Gln 1 5 10 15 Asp Phe Val Gln Trp Leu Met Asn Thr 20 25 <210> 10 <211> 25 <212> PRT <213> Artificial Sequence <220> <223> C-terminal peptide containing pseudoprolines pFT and pDS <220> <221> XA <222> (2)..(3) <223> Phe-Thr pseudoproline dipeptide <220> <221> XA <222> (11)..(12) <223> Asp-Ser pseudoproline dipeptide <400> 10 Thr Xaa Xaa Ser Asp Tyr Ser Lys Tyr Leu Xaa Xaa Arg Arg Ala Gln 1 5 10 15 Asp Phe Val Gln Trp Leu Met Asn Thr 20 25 <210> 11 <211> 25 <212> PRT <213> Artificial Sequence <220> <221> <222> (1)..(29) <223> Glucagon sequence including pDS <220> <221> XA <222> (15)..(16) <223> Asp-Ser pseudoproline dipeptide <400> 11 His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Xaa Xaa 1 5 10 15 Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Met Asn Thr 20 25 <210> 12 <211> 25 <212> PRT <213> Artificial Sequence <220> <221> <222> (1)..(29) <223> Glucagon sequence containing pYS <220> <221> XA <222> (10)..(11) <223> Tyr-Ser pseudoproline dipeptide <400> 12 His Ser Gln Gly Thr Phe Thr Ser Asp Xaa Xaa Lys Tyr Leu Asp Ser 1 5 10 15 Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Met Asn Thr 20 25 <210> 13 <211> 25 <212> PRT <213> Artificial Sequence <220> <221> <222> (1)..(29) <223> Glucagon sequence containing pYS and pDS <220> <221> XA <222> (10)..(11) <223> Tyr-Ser pseudoproline dipeptide <220> <221> XA <222> (15)..(16) <223> Asp-Ser pseudoproline dipeptide <400> 13 His Ser Gln Gly Thr Phe Thr Ser Asp Xaa Xaa Lys Tyr Leu Xaa Xaa 1 5 10 15 Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Met Asn Thr 20 25 <210> 14 <211> 25 <212> PRT <213> Artificial Sequence <220> <221> <222> (1)..(29) <223> Glucagon sequence containing pTS <220> <221> XA <222> (7)..(8) <223> Thr-Ser pseudoproline dipeptide <400> 14 His Ser Gln Gly Thr Phe Xaa Xaa Asp Tyr Ser Lys Tyr Leu Asp Ser 1 5 10 15 Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Met Asn Thr 20 25 <210> 15 <211> 25 <212> PRT <213> Artificial Sequence <220> <221> <222> (1)..(29) <223> Glucagon sequence containing pTS and pDS <220> <221> XA <222> (7)..(8) <223> Thr-Ser pseudoproline dipeptide <220> <221> XA <222> (15)..(16) <223> Asp-Ser pseudoproline dipeptide <400> 15 His Ser Gln Gly Thr Phe Xaa Xaa Asp Tyr Ser Lys Tyr Leu Xaa Xaa 1 5 10 15 Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Met Asn Thr 20 25 <210> 16 <211> 25 <212> PRT <213> Artificial Sequence <220> <221> <222> (1)..(29) <223> Glucagon sequence containing pFT <220> <221> XA <222> (6)..(7) <223> Phe-Thr pseudoproline dipeptide <400> 16 His Ser Gln Gly Thr Xaa Xaa Ser Asp Tyr Ser Lys Tyr Leu Asp Ser 1 5 10 15 Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Met Asn Thr 20 25 <210> 17 <211> 25 <212> PRT <213> Artificial Sequence <220> <221> <222> (1)..(29) <223> Glucagon sequence containing pFT and pDS <220> <221> XA <222> (6)..(7) <223> Phe-Thr pseudoproline dipeptide <220> <221> XA <222> (15)..(16) <223> Asp-Ser is not known. <400> 17 His Ser Gln Gly Thr Expression Ser Asp Tyr Ser Lys Tyr Leu Expression 1 5 10 15 Arg Arg Ala Gln Asp Phe Val Gln Trp Met Asn Thr 20 25

Claims

1. A method for preparing glucagon of formula I (SEQ ID NO: 1) The method comprises coupling the N-terminal tetrapeptide 1-4 with the C-terminal peptide 5-29, wherein: The C-terminal peptide is Thr(tBu)-Phe-Thr(tBu)-Ser(tBu)-Asp(tBu)-Tyr(tBu)-Ser(tBu)-Lys(Boc)-Tyr(tBu)-Leu-pDS-Arg(Pbf)-Arg(Pbf)-Ala-Gln(Trt)-Asp(tBu)-Phe-Val-Gln(Trt)-Trp(Boc)-Leu-Met-Asn(Trt)-Thr(tBu) Wherein, pDS is Asp(OtBu)-Ser[psi(Me,Me)pro]; The N-terminal tetrapeptide 1-4 is His(P)-Ser(P)-Gln(P)-Gly-OH.

2. The method according to claim 1, wherein: The method is performed by SPPS.

3. The method according to any one of claims 1 or 2, further comprising preparing the C-terminal peptide 5-29, wherein the preparation comprises the following steps: a) coupling α-amino protected threonine with a resin; b) selective cleavage of terminal protecting groups; c) coupling the subsequent α-amino protected amino acid or peptide with the deprotected amino group obtained in step b) in the presence of a coupling agent; d) repeating steps b) and c) to extend the peptide sequence; in, At least one step c) comprises coupling with a pseudoproline dipeptide.

4. The method according to claim 3, wherein: The coupling is performed in the presence of a coupling agent.

5. The method according to claim 4, wherein: Preferably, in the presence of diisopropylcarbodiimide, the coupling agent is selected from the group consisting of diisopropylcarbodiimide, dicyclohexylcarbodiimide, (benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate, 2-(7-aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate, 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate and ethyl-dimethylaminopropylcarbodiimide.

6. The method according to claim 3, wherein: The coupling is performed in the presence of diisopropylcarbodiimide and ethyl 2-cyano-2-hydroxyimino-acetate.

7. The method according to claim 1, wherein: The N-terminal tetrapeptide 1-4 is Boc-His(Trt)-Ser(tBu)-Gln(Trt)-Gly-OH 2a; 2a is a specific example comprising a specified protecting group.

8. Use of Boc-His(Trt)-Ser(tBu)-Gln(Trt)-Gly-OH for preparing glucagon.